"US physicians successfully regenerated a patient's badly damaged esophagus using off-the-shelf components approved by the US Food and Drug Administration and autologous platelet-rich plasma adhesive gel.
Seven years after the surgery "...
Fludeoxyglucose F 18 Injection
Use in patients with diabetes mellitus or hyperglycemia has not been well studied. It is recommended that patients be normoglycemic when undergoing PET imaging with Fludeoxyglucose F 18 Injection (fdg) .
Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides (See Drug Handling section).
Transport of Fludeoxyglucose F 18 into cells may be affected by fasting or by blood glucose changes associated with diabetes mellitus. Diabetic patients may need stabilization of blood glucose levels on the day before and on the day of administration of Fludeoxyglucose F 18 Injection (fdg) .
Carcinogenesis, Mutagenesis, Impairment or Fertility
Studies with Fludeoxyglucose F 18 Injection (fdg) have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.
Teratogenic Effects: Pregnancy Category C
Animal reproduction studies have not been conducted with Fludeoxyglucose F 18 Injection (fdg) . It is not known whether Fludeoxyglucose F 18 Injection (fdg) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, Fludeoxyglucose F 18 Injection (fdg) should be given to a pregnant woman only if clearly indicated.
It is not known whether Fludeoxyglucose F 18 Injection (fdg) is excreted in human milk. Caution should be exercised when Fludeoxyglucose F 18 Injection (fdg) is administered to a lactating woman
The safety and effectiveness of Fludeoxyglucose F 18 Injection (fdg) in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. In pediatrics, the recommended dose is 2.6 mCi. The optimal dose adjustment on the basis of body size or weight has not been determined.
The safety and effectiveness of Fludeoxyglucose F 18 Injection (fdg) for the evaluation of malignancy or for the identification of left ventricular myocardium with reversible loss of systolic function in pediatric patients below the age of 16 years have not been established.
See Clinical Trials section.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/15/2008
Additional Fludeoxyglucose F 18 Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.